A
ALT
Altimmune
3.250
+0.010+0.31%After Hours: 3.250 0.000 0.00%19:30 09/18 EDT
OPEN/PREV CLOSE2.640/2.670
TODAY RANGE2.630-2.740
VOL3.16M
MARKET CAP517.42M
52 WEEK RANGE2.560-6.44
AVG VOL (3M)4.17M
% TURNOVER1.51%
TURNOVER--
P/E (TTM)-3.4300
% RANGE4.12%
EPS(TTM)-0.7755
P/E(FORWARD)-4.5704
P/B1.091
BVPS2.438
DIVIDEND--
P/S6,650.00
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP515.12M
SHARES OUTSTANDING194.52M
NEXT EARNINGS11/04-11/09
FREE FLOAT193.66M
LOT SIZE1
EX-DATE09/14/2018
News
Press Releases
Financial Reports
Profile
TipRanks·09/29 11:29
Altimmune Appoints Richard Menziuso as Principal Accounting Officer
TipRanks·09/23 16:30
Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors
Dow Jones·09/23 13:22
Altimmune Is Maintained at Outperform by Evercore ISI Group
Dow Jones·09/23 13:22
Altimmune Price Target Cut to $17.00/Share From $18.00 by Evercore ISI Group
Benzinga·09/23 13:11
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17
TipRanks·09/23 12:00
Altimmune price target lowered to $17 from $18 at Evercore ISI
TipRanks·08/24 00:15
Altimmune Charts Long Runway with Bold Trial Push
NASDAQ·08/19 14:55
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?
NASDAQ·08/19 14:54
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus
TipRanks·08/17 09:49
Altimmune reports Q2 EPS (12c), consensus (12c)
TipRanks·08/15 13:01
Marathon, Phillips 66, Clean Energy Fuels, Altimmune, Eaton Insider Shake‑Up
Seeking Alpha·08/13 17:48
Altimmune: Pemvidutide Performs, But A Long Wait Ahead
NASDAQ·08/13 16:14
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus
Same Industry
Name/Symbol
Change%
Price